Navigation Links
New defense discovered against common hospital-acquired infection

GALVESTON Researchers have discovered a key mechanism used by intestinal cells to defend themselves against one of the world's most common hospital-acquired bacterial infections a mechanism they think they can exploit to produce a therapy to protect against the effects of the antibiotic-resistant bacteria.

The scientists made their discovery while investigating cellular responses to two powerful toxins generated by the bacteria Clostridium difficile, which can cause symptoms ranging from diarrhea to life-threatening bowel inflammation.

"About one percent of all hospital patients develop a C. difficile infection they're treated with antibiotics to the point that benign gut bacteria are knocked out, and because C. difficile is resistant to antibiotics it's able to proliferate," said University of Texas Medical Branch at Galveston associate professor Tor Savidge, lead author of a paper on the discovery to be published online Aug. 21 in Nature Medicine. "Then it releases these toxins that trigger colonic disease."

The toxins wreak havoc on cell structural proteins and biochemical communications networks, eventually killing the cell. But in order to do this damage, the toxins first have to get into the cell, and that means passing through the protective membrane that surrounds it.

It's there that Savidge and his collaborators a multidisciplinary team of researchers from UTMB, UCLA, Case Western Reserve University, Tufts University and the Commonwealth Medical College may have found a way to stop them.

On the molecular scale, C. difficile toxin proteins are quite large big enough that they have to "cleave" so that a smaller piece can slip through the membrane and into the cell. This cleavage is accomplished by a built-in molecular guillotine called a cysteine protease, which activates when the toxin encounters a molecule called InsP6 that is present at much higher levels inside the cell than outside.

"It's sort of like a sensor mechanism that detects when it's in a cell the toxins say, InsP6 is here, it's time to cleave," Savidge said. "But we've identified a previously unknown protective response that activates after the toxins have induced gut inflammation, in which the host uses a process called nitrosylation to shut down the cysteine protease and prevent cleavage."

A toxin that's unable to cleave stays stuck in the cell membrane, incapable of attacking the cell.

The researchers used test-tube, cell culture, patient specimens and animal model experiments, along with computer simulations of molecular interactions, to thoroughly explore this response and to successfully devise a way to mimic it for therapeutic purposes.

"Think of these toxins as missiles that the bacteria is producing to go off and detonate inside the cell," Savidge said. "One way to defend against missiles is to send out signals that trick them into either disarming their sensory mechanisms or get them to prematurely detonate."

Cell culture and mouse experiments demonstrated that a combination of GSNO (the nitrosylating agent and the "disarming" part of Savidge's analogy) and InsP6 (the "premature detonation" part) worked to prevent damage from C. difficile. In fact, the combination therapy worked so well that the team is now preparing to test it in a clinical trial sponsored by UTMB's Institute for Translational Sciences.

"Identification of new treatment modalities to treat this infection would be a major advance," said Dr. Charalabos Pothoulakis, director of UCLA's Inflammatory Bowel Disease Center and a co-author on the study. "If we are successful with this approach, we may be able to treat other bacterial diseases in a similar way."


Contact: Jim Kelly
University of Texas Medical Branch at Galveston

Related medicine news :

1. Malaria parasites camouflage themselves from the immune defenses of expectant mothers
2. A new line of defense against sexual assault
3. Cooling system may build eggs natural defenses against salmonella
4. Intestinal cell defense mechanism against bacteria
5. US Department of Defense supports study of brain, eye injuries in military personnel
6. Feinstein Institute to share $5M US Department of Defense grant
7. NIH funds advanced development of 3 biodefense vaccines
8. Mice with human bodys defenses
9. Key leukemia defense mechanism discovered by VCU Massey Cancer Center
10. BU School of Medicine researcher receives Department of Defense award
11. Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: